
Nihel Khoudour

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6352833/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation. Pharmaceutics, 2022, 14, 289.	2.0	2
2	Quantification of infliximab and adalimumab in human plasma by aÂliquid chromatography tandem mass spectrometryÂkitÂand comparison with two ELISA methods. Bioanalysis, 2022, 14, 831-844.	0.6	6
3	Abstract 1144: A multiplex LC-MS/MS method for assaying mAbs in oncology: Application to the CETUXIMAX GPCO-Unicancer trial on cetuximab pharmacokinetics in head and neck cancer patients. Cancer Research, 2022, 82, 1144-1144.	0.4	0
4	Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients. Pharmaceutics, 2022, 14, 1224.	2.0	3
5	Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA. Talanta, 2021, 224, 121889.	2.9	18
6	Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2021, 193, 113718.	1.4	7
7	Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and) Tj ETQq1	1 0.784314 1.7	rgBT /Overloo 10
8	Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with Elisa. Biomedicines, 2021, 9, 621.	1.4	6
9	Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. Pharmaceuticals, 2021, 14, 796.	1.7	13
10	Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study. Pharmaceuticals, 2021, 14, 804.	1.7	13
11	Gliclazide disposition in overdose $\mathbf{\hat{a}} \in$ " a case report with pharmacokinetic modeling. Clinical Toxicology, 2021, , 1-2.	0.8	1
12	Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients. Clinical Genitourinary Cancer, 2020, 18, 155-160.	0.9	13
13	Population Pharmacokinetics of Erlotinib in Patients With Non–small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. Clinical Therapeutics, 2020, 42, 1302-1316.	1.1	13
14	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. Cancers, 2020, 12, 473.	1.7	72
15	Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. Cancers, 2020, 12, 931.	1.7	12
16	ls there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?. Cancers, 2019, 11, 1784.	1.7	28
17	Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii. Journal of Antimicrobial Chemotherapy, 2017, 72, 2602-2606.	1.3	14